A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice

• Published in: Immunity (Cambridge, Mass.) Vol. 53; no. 4; pp. 724 - 732.e7
• Main Authors: Laczkó, Dorottya, Hogan, Michael J., Toulmin, Sushila A., Hicks, Philip, Lederer, Katlyn, Gaudette, Brian T., Castaño, Diana, Amanat, Fatima, Muramatsu, Hiromi, Oguin, Thomas H., Ojha, Amrita, Zhang, Lizhou, Mu, Zekun, Parks, Robert, Manzoni, Tomaz B., Roper, Brianne, Strohmeier, Shirin, Tombácz, István, Arwood, Leslee, Nachbagauer, Raffael, Karikó, Katalin, Greenhouse, Jack, Pessaint, Laurent, Porto, Maciel, Putman-Taylor, Tammy, Strasbaugh, Amanda, Campbell, Tracey-Ann, Lin, Paulo J.C., Tam, Ying K., Sempowski, Gregory D., Farzan, Michael, Choe, Hyeryun, Saunders, Kevin O., Haynes, Barton F., Andersen, Hanne, Eisenlohr, Laurence C., Weissman, Drew, Krammer, Florian, Bates, Paul, Allman, David, Locci, Michela, Pardi, Norbert
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 13.10.2020; Elsevier Limited; Cell Press
• Subjects: Animals; Antibodies; Antibodies, Neutralizing - biosynthesis; Antibodies, Viral - biosynthesis; Antigens; B-Lymphocytes - drug effects; B-Lymphocytes - immunology; B-Lymphocytes - virology; Betacoronavirus - drug effects; Betacoronavirus - immunology; Betacoronavirus - pathogenicity; CD4 antigen; CD4-Positive T-Lymphocytes - drug effects; CD4-Positive T-Lymphocytes - immunology; CD4-Positive T-Lymphocytes - virology; CD8 antigen; CD8-Positive T-Lymphocytes - drug effects; CD8-Positive T-Lymphocytes - immunology; CD8-Positive T-Lymphocytes - virology; Coronavirus Infections - genetics; Coronavirus Infections - immunology; Coronavirus Infections - pathology; Coronavirus Infections - prevention & control; Coronaviruses; COVID-19; COVID-19 Vaccines; Design; Disease Models, Animal; Furin - genetics; Furin - immunology; Humans; Immune response; Immune response (humoral); Immunity, Humoral - drug effects; Immunization; Immunization - methods; Immunogenicity; Immunogenicity, Vaccine; Immunologic Memory - drug effects; Immunological memory; Infections; Lipids; Lungs; Lymphocyte Activation - drug effects; Lymphocytes; Lymphocytes T; Memory cells; Mice; Mice, Inbred BALB C; Morbidity; mRNA; mRNA vaccine; mRNA vaccines; mRNA-LNP; Nanoparticles; Nanoparticles - administration & dosage; Nanoparticles - chemistry; nucleoside-modified mRNA; Nucleosides; Pandemics; Pandemics - prevention & control; Plasma; Pneumonia, Viral - immunology; Pneumonia, Viral - pathology; Pneumonia, Viral - prevention & control; Proteins; RNA, Messenger - genetics; RNA, Messenger - immunology; RNA, Viral - genetics; RNA, Viral - immunology; Robustness; SARS-CoV-2; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - immunology; Spike protein; Spleen; Tumor necrosis factor-TNF; Vaccines; Vaccines, Synthetic; Viral diseases; Viral Vaccines - administration & dosage; Viral Vaccines - biosynthesis; Viral Vaccines - genetics; Viruses; Zika virus; COVID-19; SARS-CoV-2; nucleoside-modified mRNA; mRNA-LNP; mRNA vaccine

SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high transmissibility of the virus and the high rate of morbidity and mortality associated with COVID-19, developing effective and safe vaccines is a top research priority. Here, we provide a detailed evaluation of the imm...